(Q28254919)

English

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22153890%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22153890%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

phase II clinical trial

0 references

multicenter clinical trial

0 references

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22153890%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Tadeusz Pieńkowski

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22153890%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22153890%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Vladimir Semiglazov

14

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22153890%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Giulia Valeria Bianchi

16

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22153890%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

10

object named as

Seock-Ah Im

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22153890%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

author name string

Young-Hyuck Im

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22153890%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Laslo Roman

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22153890%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Ling-Ming Tseng

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22153890%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Mei-Ching Liu

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22153890%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Elżbieta Staroslawska

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22153890%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Juan de la Haba-Rodriguez

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22153890%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Jose Luiz Pedrini

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22153890%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Brigitte Poirier

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22153890%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Paolo Morandi

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22153890%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Vichien Srimuninnimit

15

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22153890%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Tania Szado

17

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22153890%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Jayantha Ratnayake

18

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22153890%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Graham Ross

19

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22153890%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Pinuccia Valagussa

20

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22153890%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

language of work or name

0 references

publication date

6 December 2011

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22153890%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Lancet Oncology Commission

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22153890%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22153890%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22153890%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

25-32

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22153890%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970336-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970336-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970336-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970336-9

7 January 2021

based on heuristic

inferred from DOI database lookup

New strategies in HER2-overexpressing breast cancer: many combinations of targeted drugs available

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970336-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970336-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970336-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970336-9

7 January 2021

based on heuristic

inferred from DOI database lookup

The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970336-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970336-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970336-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of preoperative chemotherapy on the outcome of women with operable breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970336-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parall

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970336-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970336-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970336-9

7 January 2021

based on heuristic

inferred from DOI database lookup

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970336-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970336-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970336-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970336-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970336-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Lapatinib and breast cancer: current indications and outlook for the future

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970336-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970336-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Adjuvant trastuzumab in HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970336-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Combination of EGFR/HER2 tyrosine kinase inhibition by BIBW 2992 and BIBW 2669 with irradiation in FaDu human squamous cell carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970336-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970336-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Modeling the efficacy of trastuzumab-DM1, an antibody drug conjugate, in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970336-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Novel agents and future directions for refractory breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970336-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(11)70336-9

2 references

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22153890%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

2 references

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22153890%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28254919&oldid=1955588831"